Pharma player Mallinckrodt creates 40 tech R&D jobs in Dublin
Test tubes used in research. Image via Shutterstock.

Pharma player Mallinckrodt creates 40 tech R&D jobs in Dublin

19 Sep 201645 Shares

Specialty pharmaceutical player Mallinckrodt is to create 40 jobs at a new R&D facility in Blanchardstown, Dublin, as part of a €10m investment.

Mallinckrodt has a long history of operations in Ireland and has had a presence in the country for over 20 years.

Mallinckrodt had existing manufacturing operations in Ireland at Damastown, Mulhuddart, which were sold in December 2015.

‘Over more than two decades, our Irish colleagues have been a significant asset to our business’
– MARK TRUDEAU, CEO, MALLINCKRODT

The new R&D investment, supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland, reflects the ongoing transition of pharma and biotech companies from solely manufacturing to campus-like R&D operations.

Social Protection Minister Leo Varadkar said that the Irish Government has worked hard to create the right conditions for cutting-edge pharma and biopharma companies to locate in Ireland.

“The number of people at work is back up to 2m and unemployment continues to fall. This investment means more jobs and more quality jobs in our community,” Varadkar said.

R&D activities for medical devices

“We are in the process of bringing global R&D activities for medical devices to this location and the team will focus on developing systems for delivery of certain specialty pharmaceutical therapies in our portfolio,” said Mark Trudeau, president and CEO of Mallinckrodt.

“Over more than two decades, our Irish colleagues have been a significant asset to our business. We are now entering a new and exciting era for Mallinckrodt in Ireland, which will continue to play an important role in the development of our global business.”

The R&D facility will house global device engineering for the company and bring 40 new jobs to the site, bringing the overall total of new positions there to 120 by 2017.

With its May 2015 announcement and this commitment, Mallinckrodt’s total investment in the site has grown to €85 million.

“The biopharma industry is one of the fastest growing sectors in Ireland. Ireland is a leading location for the manufacture and development of biopharmaceutical medicines in the world,” said IDA Ireland CEO Martin Shanahan.

“In 2015, the sector employed over 25,000 people in Ireland and has accounted for over €30bn in exports. Biopharma companies like Mallinckrodt are currently developing and manufacturing these next generation of medicines from their base here in Dublin.”

Looking for jobs in tech or science? Check out our Employer Profiles for information on companies hiring right now.

John Kennedy
By John Kennedy

Editor John Kennedy is an award-winning technology journalist. He joined Silicon Republic in 2002 to become the fulcrum of the company’s news service He was recipient of the Irish Internet Association’s NetVisionary Technology Journalist Award 2005 and Siliconrepublic.com has been awarded ‘Best Technology Site’ at the Irish Web Awards seven times. In 2011 he received the David Manley Award commending him for his dedication to covering entrepreneurs. His interests include all things technological, music, movies, reading, history, gaming and losing the occasional game of poker.

Loading now, one moment please! Loading